Novus Acquisition and Development, Corp.
19.7.2021 14:32:37 CEST | ACCESS Newswire | Press release
Proud to be Aligned with a Proprietary Prescription Drug Benefits Powerhouse As We Begin Our Roll Out To Their Distribution Base
MIAMI, FL / ACCESSWIRE / July 19, 2021 / Novus Acquisition and Development, Corp. (OTC PINK:NDEV), through its wholly-owned subsidiary WCIG Insurance Services, LLC., is a hybrid health insurance entity and, the nation's first carrier offering cannabis health plans to recreational and medicinal users, is pleased to announce that it has finalized its partnership deal with PRAM to distribute, facilitate, and market the cannabis benefits package across the country.
PRAM, based in Brea, CA, is a leading pharmacy consulting and underwriting firm. The two companies working together will play a key role in the future of applying cannabis to American health plans as the United States approaches full federal legalization.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.Novus is proud to have come to terms with PRAM and its 32+ years of experience as a proprietary prescription Drug Benefits Consulting and Managing General Underwriter company that provides pharmacy cost containment in the marketplace. Their primary focus is:
- Employer Groups: PRAM's client base of organizations that focus on pairing PRAM's pharmacy benefit programs alongside medical and ancillary products include distribution partners, consultants, brokers, agents, and insurance carriers across the country.
- Insurance Carriers + Pharmacy Benefit Managers (PBMs): PRAM designs cost savings pharmacy programs by coordinating insurance carriers and PBMs in an effort to help clients manage pharmacy risk. As a fundamental process, PRAM's focus is to create, underwrite, manage, and market prescription drug insurance programs. These plans are advantageously paired with limited medical, short-term medical, and GAP plans. The most beneficial element to these plans is that they are guaranteed issue and ready to take to market. PRAM has many other custom product offerings in the pharmacy space aimed at saving money and creating healthier populations.
- Plan Design Choices: PRAM intends to customize the Novus cannabis offering by tailoring formularies, copays, deductibles, specialty drug coverage, and specific drug inclusions or exclusions to best benefit the member experience.
Lisa Collier, CEO of PRAM, states: "Such innovation is at the core of PRAM's growth strategies and benefit design goals, so we are thrilled to be a part of a program that screams forward-thinking. National legalization is coming, and we'd rather be leading the dispensary network discount initiative than lagging behind it."
Frank Labrozzi, CEO of Novus, states: "It is of critical importance in business to foresee coming events. Our mission is to have the right alliance in preparation for that change. PRAM will provide that company partnership necessary for opening doors that once were challenges."
Alignment Competitive Advantages:
With the PRAM alliance, Novus is positioned to play a greater role in the future in the following areas:
- More doctors will recommend medical cannabis as participation in reducing opiate prescriptions.
- Take the stigma out of cannabis in the workplace with precedence set in the New Jersey Supreme Court, that ruled, under the New Jersey Law Against Discrimination ("LAD"), employees who legally use cannabis as permitted by the state's Compassionate Use of Cannabis of Medical Marijuana Act[i] may not be fired.
- Ending prohibitions we could see a dramatic increase in our Provider Network where the big box and boutique retailers will likely sell pre-packaged cannabis in smokable and edible forms.
As Washington has to make up for a $6 Trillion dispersal of money in the past 18 months, there has never been a more critical time to legalize cannabis. More importantly, by ending prohibition of cannabis we will see med and rec users encouragingly help support our economy as they choose to have cannabis as a part of health insurance benefits.
Research Novus Now:
- Financial Filings: Click Here
- Quote: Click Here
- Website: Click Here
- Investor's Page: Click Here
About PRAM
PRAM Insurance Services, Inc. was founded in 1989 by David P. Wilson. Dave has been in the insurance industry for over 40 years, and he has focused exclusively on prescription drug benefits since the beginning of PRAM when he identified a unique need for pharmacy cost containment in the marketplace.
For additional information on PRAM, please visit https://pram.com.
About Novus
Novus Acquisition & Development Corp. (NDEV), through its subsidiary WCIG Insurance, provides health insurance and related insurance solutions within the wellness and medical marijuana industries in states where legal programs exist. Novus has developed its infrastructure within many lines of the insurance business such as health, property & casualty, life, accident, and fixed annuities.
Novus' medical cannabis benefits package will work as outside developers and will not cultivate, handle, transport grow, extract, dispense, put up for sale, put on the market, vend, deliver, supply, circulate, or trade cannabis or any substances that violate the United States law or the Controlled Substances Act, nor does it intend to do so in the future and will continue to follow state and federal laws. The statements made about specific products have not been evaluated by the United States Food and Drug Administration (FDA) and are not intended to diagnose, treat, cure, or prevent disease. All information provided on these press releases or any information contained on or in any product label or packaging is for informational purposes only and is not intended as a substitute for advice from your physician or other health care professional. Once a push notification is completed the transaction is solely between the state-licensed dispensary and the registered patient.
The state laws are in conflict with the federal Controlled Substances Act. The current administration has effectively stated that it is not an efficient use of resources to direct federal law enforcement agencies to prosecute those lawfully abiding by state-designated laws, allowing the use and distribution of medical marijuana. However, there is no guarantee that the current administration, nor any future administration, will not change this policy and decide to enforce the federal laws strongly.
Any such change in the federal government's enforcement of current federal laws could cause significant financial changes to Novus Medical Group. While we do not intend to harvest, distribute or sell cannabis or cannabis-related products, we may be harmed by a change in enforcement by federal or state governments.
Forward-Looking Statements
This release includes forward-looking statements, which are based on certain assumptions and reflect management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, includes codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. Membership and providers may change, become inactive, or nonpaying from time to time. Novus disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Investor Contact Information
855-228-7355
Email: info@getnovusnow.com
SOURCE: Novus Acquisition and Development Corporation
View source version on accesswire.com:
https://www.accesswire.com/655983/Novus-Signs-Partnership-With-PRAM-a-Leading-Pharmacy-Consulting-and-Underwriting-Firm
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Iggy Azalea Invests in Shift - The AI Company Behind the Fastest-Growing Platform in the $1.3 Trillion Creator Economy, Fanvue27.8.2026 14:00:00 CEST | Press release
The Grammy-nominated artist and entrepreneur has made a significant investment in SHIFT, whose AI infrastructure has propelled its flagship platform, Fanvue, from a $4m to $200m annualised run rate in just over 2 years. LONDON, UK / ACCESS Newswire / August 27, 2026 / Iggy Azalea, the four-time Grammy-nominated artist, entrepreneur, and active investor, has personally invested a substantial sum in Fanvue's parent company SHIFT - the AI infrastructure the platform runs on. As part of the investment deal, Azalea will also become the founding member of SHIFT's Creator Advisory Board. The move comes at a time when the world's biggest creators, athletes and music artists are increasingly looking to multi-million-dollar equity opportunities in the creator economy - recent examples include MrBeast and the Paul brothers, Jake and Logan. AI is transforming how people make money online. For two decades, the creator economy has run on a simple trade: creators build the audience, and advertisers r
ZAGENO and ORO Labs Partner to Connect Scientific Purchasing with Enterprise Procurement26.8.2026 14:35:00 CEST | Press release
Partnership combines ORO Labs' AI-native procurement orchestration platform with ZAGENO's scientific marketplace and supplier network to deliver a governed, end-to-end purchasing experience for life sciences R&D. BOSTON, MA / ACCESS Newswire / August 26, 2026 / ZAGENO, the scientific procurement platform connecting researchers with 75 million laboratory products from approximately 5,500 suppliers, today announced a strategic partnership with ORO Labs, the AI-native procurement orchestration platform. The partnership connects ORO Labs' enterprise intake, workflow, and approval capabilities with ZAGENO's scientific product discovery, marketplace, supplier network, and fulfillment infrastructure. Together, the companies enable a single governed journey from request and approval through product selection, ordering, and fulfillment. Scientific R&D procurement has specialized requirements. Researchers need fast, intuitive access to highly specific products, while procurement teams need polic
Eudia Accelerates Enterprise AI Transformation with Google Cloud's Gemini Enterprise for Legal25.8.2026 15:50:00 CEST | Press release
PALO ALTO, CA / ACCESS Newswire / August 25, 2026 / Eudia, the augmented intelligence platform for enterprise legal, contracting, and compliance, today announced a partnership with Google to launch new industry-specific AI capabilities on Google Cloud's Gemini Enterprise for Legal. Eudia's agent scales the legal, contracting, and compliance expertise of an organization's top operators to every team in the enterprise. Built on Google's Agent Development Kit and connected via MCP, Eudia combines a suite of specialized agents with digital twins of domain-scoped institutional knowledge, orchestrated with legal-specific reasoning and access to legal databases. Eudia enables Legal, Compliance, Procurement, and Revenue teams to draft and review contracts, analyze marketing assets for compliance, assess risk across thousands of executed contracts, and manage obligations across the entire company portfolio, giving large enterprises a faster path to trusted, governed legal AI. In practice, this
Envision Pharma Group Names Ryan Tubbs, Senior Vice President, Commercial Growth25.8.2026 15:00:00 CEST | Press release
New role unifies sales enablement, lead generation, and marketing under centralized leadership and expands oversight to customer success, supporting a consistent, connected client experience across Envision. FAIRFIELD, CT / ACCESS Newswire / August 25, 2026 / Envision Pharma Group (Envision) has appointed Ryan Tubbs as Senior Vice President, Commercial Growth. In this newly created role, Tubbs will lead the centralized Commercial Growth function spanning sales enablement, lead generation, marketing, and client success. He will also help shape Envision's commercial strategy and operating model to accelerate enterprise growth. Tubbs' remit also includes the Client Implementation and Client Experience teams. Connecting Envision's pre-sale and post-sale capabilities will create a more integrated commercial engine, making it easier for teams to bring the best of Envision to clients and for clients to realize value quickly. The timing is notable as Envision's iEnvision®, market access, and m
Polaris Renewable Energy Announces Renewal of Normal Course Issuer Bid25.8.2026 13:50:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / August 25, 2026 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris" or the "Company") today announced that the Toronto Stock Exchange ("TSX") has accepted its notice of intention to renew its normal course issuer bid ("NCIB"). The Company's Board of Directors believes that an NCIB represents an appropriate and desirable use of its available free cash to increase shareholder value and is in the best interest of the Company and its shareholders. Pursuant to the notice, Polaris may purchase up to 2,021,205 of its common shares ("Shares"), representing approximately 10% of the public float of 20,212,059 Shares as at August 13, 2026, during the twelve month period commencing August 27, 2026 and ending August 26, 2027, provided that the board of directors of Polaris has initially limited the NCIB to repurchase up to 176,872 Shares. As at August 13, 2026, there were 20,895,285 Shares issued and outstanding. Under the NCIB, other than purchases made under block
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
